Burke:

Overview

  • This article provides an evidence-based review of the diagnostic assessment for DSM-5 Disruptive, Impulse Control, and Conduct Disorders (DBDs): Oppositional Defiant Disorder (ODD), Conduct Disorder (CD), Antisocial Personality Disorder (APD), and Intermittent Explosive Disorder (IED).

  • It also discusses disruptive mood dysregulation disorder (DMDD) and key dimensions of ODD and CD due to their relevance for assessing DBDs.

  • Main message: use multiple information sources (e.g., clinical interview, standardized rating scales/checklists) and multiple informants (e.g., parent, teacher, self-report) to reduce biases and improve diagnostic accuracy; follow diagnostic guidelines closely; be mindful of stigma, trauma history, race and gender biases; and consider dimensional versus categorical approaches.

Key Concepts and Definitions

  • Disruptive behavior disorders (DBDs) include ODD, CD, APD, IED; DMDD is discussed due to overlap with irritability dimensions.

  • Core feature across DBDs: harmful behaviors toward others or norms, with nuanced distinctions:

    • ODD: chronic oppositional behavior and hostile/irritable interpersonal interactions; aggression is not required.

    • CD: must include aggressive behaviors plus property damage, theft, or rule violations; includes deficits in prosocial emotions (LPE).

    • APD: pervasive disregard for others and societal norms; may include impulsivity, irresponsibility, fights; requires age 18+ with prior evidence of conduct problems before age 15.

    • IED: intense, reactive aggressive outbursts; not other DBD symptoms predominating.

    • DMDD: chronic irritability and severe temper outbursts; overlaps with ODD; distinct considerations in assessment and cross-diagnostic context.

  • DSM-5 vs ICD-11: ICD-11 includes chronic irritability/anger as a potential subtype/feature within ODD; DSM-5 discourages a formal chronic irritability syndrome within ODD, though irritability is a key dimension.

  • Four core dimensions proposed for early irritability and behavior (dimension-based approach): noncompliance, irritability, aggression, callousness; dimensional models may better capture heterogeneity than strict categories, though evidence is mixed on whether dimensional models outperform categorical diagnoses in practice.

  • Important empirical points:

    • There is substantial overlap among DBDs and with other disorders (e.g., DMDD, ADHD, mood disorders) and with risk factors (trauma, family history).

    • Stigma around DBDs is debated; empirical evidence for diagnosable harm from DSM labeling is limited, but clinicians should be mindful of potential bias and costs/benefits of labeling.

    • Multi-informant data improve assessment; informant discrepancies reflect context differences and are informative rather than purely erroneous.

    • Assessment should be developmentally appropriate and sensitive to lifespan changes (ODD/CD seen in preschool to adulthood; DMDD developmentally anchored in childhood).

  • Key numerical references (examples):

    • CD criteria:
      extCDrequiresatleast3extof15symptomswithinthepastyear,withatleastonesymptominthepast6months.ext{CD requires at least }3 ext{ of 15 symptoms within the past year, with at least one symptom in the past 6 months}.

    • ODD: DSM-5 criteria are organized under three headings: Angry/Irritable Mood, Argumentative/Defiant Behavior, and Vindictiveness.

    • DMDD prevalence estimates span a wide range:
      P(extDMDD)extestimatesrangefrom0.1ext%to7%extincommunitysamples,withsomeestimatesaround3%.P( ext{DMDD}) ext{ estimates range from } 0.1 ext{\% to }7\% ext{ in community samples, with some estimates around }3\%.

    • Lifetime prevalence of CD:
      P(extCD)extlifetime9.5%.P( ext{CD})_{ ext{lifetime}} \approx 9.5\%.

    • Lifetime prevalence of ODD: epidemiological data place lifetime prevalence around roughly $10.2\%$ (Nock et al., 2007).

    • IED lifetime prevalence:
      P(extIED)extlifetime0.1%extto2.7%.P( ext{IED})_{ ext{lifetime}} \approx 0.1\% ext{ to } 2.7\%.

    • ODD test–retest reliability for diagnostic interviews: parent interview $k = 0.59$; child interview $k = 0.39$ (higher reliability when including parent/caregiver input).

    • APD prevalence in adults: roughly $3\%$ to $5\%$, with a subset of individuals showing broader psychopathic traits; race and sex differences exist in measurement and prevalence.

  • Diagnostic tools and measures are organized by disorder and by purpose (interviews vs. rating scales vs. multi-informant instruments). Specific tools are listed in Tables 1 and 2 of the article; here we summarize representative examples.

Factors Affecting Clinical Judgment in DBD Assessment

  • Stigma

    • Clinician concern: labeling may stigmatize; empirical evidence for actual harm from diagnosis is limited, though perceptions influence clinical practice.

    • Some research suggests stigma is more evident when diagnoses combine behavioral and emotional disorders rather than behavioral disorders alone.

    • Benefits of diagnosis include access to evidence-based treatment, prognosis, and academic supports; research is needed to quantify real-world costs and benefits of labeling.

  • Trauma (potential traumatic events, PTEs)

    • Clinician belief that behavioral disorders are trauma-driven can bias judgment.

    • Be mindful that trauma is a risk factor for DBDs and that DBDs and PTSD can co-occur; the presence of trauma should not rule out a DBD diagnosis.

    • Ethical approach: complete, accurate diagnostic assessment including DBDs when appropriate.

  • Racial Bias in Diagnostic Practice

    • Minority youths may be misdiagnosed with DBDs more often, with alternative diagnoses (e.g., ADHD, autism, mood disorders) sometimes more appropriate.

    • Race concordance between clinician and patient may mitigate or exacerbate bias; education and targeted bias-reduction strategies are recommended.

    • Strategies to reduce bias include education, training activities, and systemic interventions; training and evidence-based assessment are needed to improve reliability/validity.

  • Gender Bias in Diagnostic Practice

    • Historically more DBD diagnoses in males (e.g., CD), though symptom patterns and aggression levels may differ by gender.

    • Clinicians should adhere to DSM-5 criteria and be cautious of unconscious gender beliefs; algorithmic and statistical approaches may help reduce bias.

  • Practical implication: biases can distort the diagnostic process, but with explicit attention to guidelines, multi-informant data, and robust assessment methods, clinicians can mitigate bias and improve accuracy.

General Assessment Best Practices for DBDs

  • Diagnostic assessment should be a multistep process:

    • Clarify the purpose of the assessment (e.g., treatment planning, differential diagnosis).

    • Develop a diagnostic formulation that informs case conceptualization and treatment planning.

    • Recognize that diagnoses are helpful but not always central to understanding presenting problems; not all symptoms meet criteria for a diagnosis or are clinically central.

    • Screen out diagnoses or consider differential diagnoses when warranted; consider sleep, stress, and wellness behaviors that affect functioning.

  • Standards for assessment in the field:

    • Clinicians must integrate information across sources to produce a sound diagnostic formulation; many clinicians still do not consistently reference guidelines.

    • Large-scale data indicate a substantial proportion of clinicians provide diagnoses without consulting diagnostic guidelines, highlighting a gap between practice and evidence-based standards.

    • Clinical practice must be anchored in empirical knowledge about comorbidities and development, not just clinical intuition.

  • Assessment Methods (overview):

    • Use behavioral rating scales and structured/semi-structured diagnostic interviews to obtain broad symptom coverage and to increase identified diagnoses compared with unstructured interviews.

    • Training and time considerations exist for standardized interviews; one practical approach is to use rating scales first to screen areas of concern, then administer targeted interview modules.

    • Tables 1 and 2 in the article list tools for ODD, CD, LPE, DMDD, APD, and IED (interviews and rating scales).

  • Informant Effects and Multi-Informant Assessment

    • Informants (parents, teachers, self-report) often show low interrater agreement; this is not merely measurement error but may reflect genuine context differences.

    • Collecting information from multiple informants enhances assessment; discrepancies can be informative for prognosis and treatment planning.

    • If criteria are met based on a single informant, the information still carries prognostic risk and should not be discounted.

    • In children, parents and teachers provide complementary views; in adults, collateral informants (e.g., partners, coworkers) can be more challenging to obtain but valuable.

  • Informant integration and measurement considerations:

    • Use a combination of interviews and rating scales to maximize coverage and efficiency.

    • Consider developmentally appropriate methods across the lifespan (preschool, school-age, adolescence, adulthood).

  • Informant- and method-related evidence bases:

    • A large body of work supports multi-informant approaches and convergent validity across informants when integrated properly.

    • The literature emphasizes the need for developmentally sensitive measures and cross-informant data integration, particularly for DMDD and irritability dimensions.

  • Tools: a snapshot of assessment options (representative examples from Tables 1 and 2):

    • Interviews (ODD and related): CAPA (Angold & Costello, 2000); CHIPS (Weller et al., 2000); DAWBA (Developmental and Well-Being Assessment); DICA-PPYC; DIPA; DISCAP-5; K-SADS-PL-5; MINI KID; PAPA; WRAADS.

    • Prosocial Emotions (LPE) related: CAPE; M-LPE.

    • Rating scales for ODD/CD/LPE: ABI-YA; ASROS-5; CABI; CASI-5; DBDRS; K-CAT; NICHQ Vanderbilt; SNAP-IV; CPTI; PSCD.

    • Summary observation: parent/teacher reports often show high utility for cross-informant screening and differential diagnosis.

  • Dimensionality vs discrete categories (revisited)

    • Categorical diagnoses provide clear clinical decision utility (e.g., treatment matching).

    • Dimensional models may capture heterogeneity within and across disorders, with proposed models (e.g., Wakschlag et al., 2017) highlighting noncompliance, irritability, aggression, and callousness as core dimensions.

    • Empirical evidence on whether dimensional models outperform categorical models is mixed (ambiguous results in Krueger et al., 2021; Thöne et al., 2022).

    • For ODD in particular, dimensions (irritable vs. defiant) have shown prognostic relevance, but guidance on chronic irritability within ODD remains limited; ICD-11 provides more explicit irritability-based distinctions within ODD.

Oppositional Defiant Disorder (ODD)

  • DSM-5 criteria and structure

    • DSM-5 organizes ODD symptoms under three categories: Angry/Irritable Mood; Argumentative and Defiant Behavior; Vindictiveness.

    • ODD criteria emphasize irritability and defiant behaviors; aggression is not required, but irritability has prognostic utility for internalizing and externalizing outcomes.

    • DSM-5 does not specify subtypes within ODD, though ICD-11 includes irritability-based subtypes.

  • Dimensional considerations for ODD

    • Distinguishing irritable vs. defiant symptom dimensions is supported by factor-analytic work; these dimensions may have different prognostic implications (e.g., risk for depression/anxiety versus antisocial behavior).

    • In preschool-aged children, dimensional approaches can help identify chronic irritability and its treatment implications; however, no clear empirical guideline dictates a categorical vs dimensional cutoff for irritability within ODD.

  • Diagnostic Interviews for ODD

    • Widely used interviews: K-SADS-PL-5; CAPA; DISK/DISCAP-5; DIPA; PAPA; PAPA; WRAADS; others.

    • Web-based self-admin versions for parent/child reports have shown promising psychometric properties (e.g., K-SADS-PL-5 web versions).

    • In many cases, DSM-IV interviews remain acceptable when updating to DSM-5 standards; nonetheless, DSM-5-compatible instruments are preferred.

  • Rating Scales for ODD

    • Notable tools: CABI; CASI-5; DBDRS; Swanson, Nolan, and Pelham Rating Scale (SNAP-IV); K-CAT (Kiddie Computerized Adaptive Test) for rapid dimensional assessment; NICHQ Vanderbilt scales.

    • CABI has supportive evidence for preschool samples; SNAP-IV and CASI-5 are widely used across ages.

  • Assessing ODD Across the Lifespan

    • Epidemiology: approximately 10.2% of individuals experience ODD over their lifetime (Nock et al., 2007).

    • Preschool/early childhood: best-practice approaches do not pathologize normative behavior; can differentiate chronic irritability vs. oppositional behavior; developmentally appropriate interview methods (e.g., PAPA, DISCAP-5) are recommended.

    • Adult presentations: early work supports reliability/validity of adult ODD measures (e.g., Adult Self-Report of ODD Symptoms; WARA-like measures); overall, DSM-5 criteria can identify ODD in adulthood with reasonable accuracy.

  • ODD across informants

    • Parent and teacher reports independently link with broader psychopathology; multi-informant data improve assessment accuracy and prognosis.

  • Summary for ODD: tetrad of symptoms instead of a single dimension; integration of irritability and noncompliance is crucial for prognosis and treatment planning.

Conduct Disorder (CD)

  • Diagnostic criteria and prevalence

    • CD criteria: 15 symptoms across four categories: Aggression to People/Animals; Destruction of Property; Deceit/theft; Serious Violations of Rules.

    • Must show at least 3 of 15 symptoms within the past year, with at least one symptom in the past 6 months.

    • Lifetime prevalence of CD is approximately P(extCD)extlifetime0.095P( ext{CD})_{ ext{lifetime}} \approx 0.095 (9.5%).

  • Limited Prosocial Emotions (LPE) specifier

    • New in DSM-5 CD: LPE specifier for a subset with callous-unemotional features.

    • LPE requires at least two of four: lack of remorse or guilt; callousness; unconcerned about performance; shallow or deficient affect; persistent across multiple relationships/settings for at least 12 months.

    • Evidence supports LPE identifying a distinct subgroup with different prognosis and treatment responsiveness; however, some studies question its utility in all contexts (e.g., some populations, broader psychopathy models).

  • CD across the lifespan

    • CD can be diagnosed in preschoolers with LPE using appropriate measures; DISCAP-5 and other DSM-5-aligned tools have demonstrated validity in young children (e.g., 2-year-olds for CD/LPE assessment).

    • CD can also be diagnosed in adulthood; the APD section discusses the continuity and distinctions between CD with lifetime manifestations and APD.

  • Diagnostic interviews and measures for CD

    • DMDD and LPE-related instruments include: Clinical Assessment of Prosocial Emotions (CAPE 1.1); Michigan Limited Prosocial Emotions (M-LPE); DISCAP-5; PSCD (Proposed Specifiers for Conduct Disorder).

    • PSCD tools provide a multidimensional empathy/psychopathy framework (CU/LPE, grandiose-manipulative, daring-impulsive) but do not cover all CD symptoms; self-report versions validated in various countries.

    • Rating scales for CD/LPE: CASI-5 (parent/teacher versions); CABI (measures LPE but not CD); PSCD scales (self- and parent-report; for bereft of full CD symptom coverage).

  • CD across informants and lifespan

    • Similar to ODD, multi-informant data improve diagnostic validity; cross-informant convergence is not always high but informs clinical risk and treatment needs.

  • CD-specific cautions and debate

    • Some argue for broader multidimensional models of psychopathy beyond LPE (to include grandiose-manipulative and daring-impulsive traits).

    • The AMPD framework and DSM-5 personality disorder approaches inform dimensional assessment of antisocial traits in adults.

  • Across evidence base: CD assessment emphasizes LPE as a meaningful specifier; strong emphasis on multi-informant, cross-setting observation and developmentally sensitive measurement.

Disruptive Mood Dysregulation Disorder (DMDD)

  • Conceptualization

    • DMDD is a depressive-disorder classification in DSM-5, designed to capture chronic irritability and severe temper outbursts in youth; it cannot co-occur with bipolar disorder.

    • DMDD originated from research on chronic irritability and its distinction from pediatric bipolar disorder.

  • Diagnostic criteria and prevalence

    • Two primary symptoms:

    • Severe and recurrent temper outbursts, at least 3 times per week, with aggression that is developmentally inappropriate.

    • Persistent irritable or angry mood most of the day, nearly every day, between outbursts.

    • Symptoms present for at least 12 months, in at least two of three settings (home, school, peers), severe in at least one setting; onset before age 10; diagnosis not before age 6 or after age 18.

    • Community prevalence estimates range from <1% (0.1%–3.3%) to 7%, with Laporte et al. (2021) converging around ~3%.

    • DSM-5 excludes DMDD co-occurrence with ODD or IED; if full presentation coexists with either, DMDD is diagnosed alone.

  • Relationship to other disorders

    • DMDD often co-occurs with externalizing and internalizing problems and overlaps with ODD symptoms; ICD-11 treats chronic irritability as a subtype within ODD in some contexts.

    • The DMDD literature has distinct measurement challenges; some tools overlap with irritability and aggression in other disorders.

  • Assessment approaches and measures

    • Irritability and outbursts are central symptoms; reliability/validity of measures vary.

    • Common tools cited for irritability/DMDD assessment include:

    • Affective Reactivity Index (ARI) and Clinician ARI (CL-ARI)

    • Aberrant Behavior Checklist irritability subscale (ABC)

    • Multidimensional Assessment of Preschool Disruptive Behavior (MAP-DB)

    • Retrospective Modified Overt Aggression Scale (R-MOAS)

    • Outburst Monitoring Scale (OMS)

    • Emotional Outburst Inventory (EMO-I)

    • DMDD measurement remains limited; there is ongoing work on multi-informant, multimethod integration (De Los Reyes et al., 2015; Burke et al., 2020).

    • DMDD-related development of DMDD-focused interviews is limited; K-SADS-5 includes DMDD/SMD in updated DSM-5 versions.

  • Lifespan and cross-national considerations

    • DMDD prevalence and detection show gender differences (some studies suggest male preponderance); cross-national field studies report challenges in reliable DMDD diagnosis across countries.

    • Ecological momentary assessment (EMA) is a promising method for capturing contextual triggers and frequency/duration of irritability and outbursts in real time.

  • Summary implications for DMDD assessment

    • DMDD assessment requires careful differentiation from ODD symptoms and bipolar disorder; emphasize irritability and temper outbursts while considering comorbidity.

    • There are few validated, DMDD-specific instruments; integration of multi-informant data and developmentally appropriate measures is critical.

Antisocial Personality Disorder (APD)

  • Diagnostic criteria and context

    • APD requires 18+ years of age for diagnosis; prior symptoms must have been evident before age 15.

    • APD features include a pervasive pattern of disregard for and violation of the rights of others, with criteria including several facets such as deceitfulness, impulsivity, aggressiveness, and risk-taking.

    • In DSM-5, APD sits in both the Personality Disorders section and the Disruptive, Impulse-Control, and Conduct Disorders section, reflecting its overlap with CD.

  • Relationship to CD

    • Since CD with LPE specifier exists, the distinction between APD and CD is less clear in adults; some individuals meet criteria for both or transition from CD in youth to APD in adulthood.

  • Prevalence and associated factors

    • APD prevalence in adults is estimated around 3%–5% in the U.S., with higher rates in certain populations and domains.

    • A subset of adults with APD show psychopathy features; this overlap with psychopathy has distinct measurement implications in forensic samples.

  • Assessment tools and approaches

    • Multi-informant and multi-method approaches are recommended; collateral informants (e.g., partners, coworkers) can be challenging to obtain but valuable.

    • Traditional personality assessment tools include:

    • Personality Diagnostic Questionnaire-4 (PDQ-4)

    • Personality Assessment Inventory (PAI)

    • Psychopathy-focused measures are widely used in forensic contexts:

    • Psychopathy Checklist-Revised (PCL-R)

    • Triarchic Psychopathy Measure (TriPM)

    • Psychopathy Personality Inventory-Revised (PPI-R)

    • PID-5 (DSM-5 trait model) with psychopathy-relevant dimensions

  • Dimensional frameworks and AMPD

    • The Alternative Model of Personality Disorders (AMPD) proposes two components: Criterion A (level of personality functioning) and Criterion B (five-domain traits).

    • When applied to APD, Criterion A includes deficits in prosocial behavior and egocentrism; Criterion B includes traits such as manipulativeness, hostility, deceitfulness, callousness, risk-taking, irresponsibility, and impulsivity; a psychopathy specifier is noted within AMPD discussions.

  • Measurement considerations

    • The literature acknowledges potential sex/gender differences in factor structure and predictive validity for violence and reoffending; this warrants careful interpretation in mixed samples.

Intermittent Explosive Disorder (IED)

  • Diagnostic overview

    • IED is an impulse-control disorder characterized by frequent, intense, impulsive aggressive outbursts with poor match to preceding stressors; outbursts may be toward people, property, or both.

    • IED shows high comorbidity with other psychopathologies (ODD, CD, substance use disorder).

  • Prevalence and onset

    • Global mean onset around age 17; lifetime prevalence estimates range from roughly 0.1%to2.7%0.1\% \, to \, 2.7\%.

    • IED can be diagnosed as young as age 6; longitudinal stability evidence exists but is limited.

  • Diagnostic and measurement tools

    • Diagnostic interviews: Structured Clinical Interview for DSM-5 (SCID); SIDP (Structured Interview for DSM-IV Personality Disorders); IED-M (IED Interview-Modified); IED-SQ (IED Screening Questionnaire).

    • Other supplementary measures for aggression and impulsivity:

    • Life History of Aggression (LHA)

    • Buss-Perry Aggression Questionnaire (BPAQ)

    • State-Trait Anger Expression Inventory-II (STAX-II)

    • Hostile Automatic Thoughts (HAT) scale

    • Overt Aggression Scale Modified (OAS-M)

  • Measurement considerations and gaps

    • There are relatively few IED-specific diagnostic tools validated for clinical settings; much reliance on research instruments (SCID, SIDP, IED-M) with limited evidence for clinical utility of some tools (e.g., IED-SQ not validated in clinical settings).

    • OAS-M has been used in clinical trials and can track change in aggressive symptoms during treatment; more work is needed to establish cross-clinical validity.

  • Future directions

    • There is a need for brief, psychometrically strong, multi-informant measures of IED, especially for children and adolescents.

    • Emphasis on diverse samples and cross-informant data to improve generalizability of IED assessment and its treatment implications.

DMDD, ODD, CD, APD, IED: Cross-Disorder Considerations

  • DMDD and ODD relationship

    • DMDD overlaps with ODD in irritability and temper outbursts; measurement strategies need to distinguish chronic irritability from oppositional/defiant behavior.

    • Some developmentally tailored measures may inadvertently conflate irritability and oppositionality; careful item design is needed in DMDD-focused instruments.

  • ICD-11 vs DSM-5 approaches

    • ICD-11 offers irritability-based subtypes for certain presentations and may diverge from DSM-5 in how irritability is classified, highlighting the importance of cross-diagnostic research.

  • Dimensional versus categorical pathways

    • While categorical diagnoses support clinical decision-making and guideline concordance, dimensional models may capture heterogeneity and trajectories better; the evidence is mixed and context-dependent.

  • Informant integration and multi-method approaches

    • The consensus underscores using multiple informants and methods (interviews plus rating scales) across development stages and disorders to maximize validity.

  • Cross-cultural and lifespan considerations

    • Cross-cultural validity of DMDD and irritability measures remains a key research area; field studies show some challenges in cross-national reliability.

    • Across the lifespan, tools for adults with DBDs (e.g., APD) are developing, with special attention to AMPD framework and psychopathy-related measures.

Assessment Tools: Tables 1 and 2 (Representative Examples)

  • Table 1: Assessment Tools for ODD, CD, and LPE

    • Interviews (examples):

    • CAPA (Child and Adolescent Psychiatric Assessment)

    • CHIPS (Children’s Interview for Psychiatric Syndromes)

    • DAWBA (Developmental and Well-Being Assessment)

    • DICA-PPYC (Diagnostic Interview for Children and Adolescents for Parents of Preschool and Young Children)

    • DIPA (Diagnostic Infant and Preschool Assessment)

    • DISCAP-5 (Diagnostic Interview Schedule for Children Adolescents and Parents 5)

    • K-SADS-PL-5 (Kiddie Schedule for Affective Disorders and Schizophrenia, Present and Lifetime Version, DSM-5)

    • MINI-KID (Mini International Neuropsychiatric Interview for Kids)

    • PAPA (Preschool Age Psychiatric Assessment)

    • WRAADS (Wender-Reimherr Adult ADHD Scale)

    • LPE measures: CAPE (Clinical Assessment of Prosocial Emotions), M-LPE (Michigan Limited Prosocial Emotions)

    • Rating scales (examples):

    • ABI-YA (Antisocial Behavior Index for Young Adulthood)

    • ASROS-5 (Adult Self-Report of ODD Symptoms for DSM-5)

    • CABI (Child and Adolescent Behavior Inventory)

    • CASI-5 (Child and Adolescent Symptom Inventory)

    • DBDRS (Disruptive Behavior Disorder Rating Scale)

    • K-CAT (K-CAT)

    • NICHQ Vanderbilt Scales

    • SNAP-IV

    • CD & LPE measures: CPTI (Child Problematic Traits Inventory), PSCD (Proposed Specifiers for Conduct Disorder)

  • Table 2: Assessment Tools Related to DMDD, APD, and IED

    • DMDD: ARI, CL-ARI, ABC, MAP-DB, R-MOAS, OMS, EMO-I

    • APD: PDQ-4, PAI; PCL-R (psychopathy), TriPM, PPI-R, PID-5

    • IED: SCID, SIDP, IED-M, IED-SQ, LHA, BPAQ, STAX-II, HAT, OAS-M

  • Note: Many measures have been updated or designed for DSM-5; some measures were originally DSM-IV and later updated.

Assessment Across the Lifespan and Cross-Cultural Considerations

  • Lifespan notes

    • ODD can be identified in preschoolers with developmentally appropriate interviews; validity of DMDD and irritability measures has grown but requires caution in younger populations.

    • In adulthood, some ODD-like symptoms and CD/LPE features can be observed; several adult-oriented measures (e.g., ARI-based and adult psychopathy tools) exist but require careful interpretation.

  • Cross-cultural considerations

    • International field studies show variability in diagnostic performance for DMDD and irritability; cross-national measurement work is ongoing.

    • Cross-cultural data emphasize the need for culturally valid instruments and measurement invariance across populations.

  • Implications for practice

    • Clinicians should pursue a broad, multi-method approach with multiple informants to accommodate context-specific behavior and reduce misdiagnosis due to bias.

    • Clinicians should maintain a careful balance between recognizing clinically meaningful symptoms and avoiding over-pathologizing normative development, especially in preschoolers.

Conclusions and Practical Takeaways

  • The central guidance: follow DSM-5 diagnostic guidelines closely and use a broad, evidence-based assessment approach that combines interviews, rating scales, and structured diagnostic tools, ideally across multiple informants.

  • The benefits of a robust assessment include improved accuracy, more precise differential diagnosis, better treatment planning, and the ability to build a stronger educational/clinical support plan for the child or adult.

  • Ongoing needs in the field:

    • More empirical work on stigma related to DBD diagnoses and its real-world costs/benefits.

    • More reliable cross-cultural measurement tools for DMDD and irritability; better multi-informant integration methods, particularly for DMDD and IED in youth.

    • Further development and validation of brief, multi-informant measures for IED and APD across diverse populations.

  • Final exhortation: diagnoses describe problems and guide treatment, not define the person; careful and transparent diagnostic processes maximize treatment planning and outcomes.

References and Context (Selected)

  • DSM-5 and DSM-5-TR updates; ICD-11 considerations.

  • Foundational texts and key studies cited include, among others: Lahey (2021) on dimensional classifications; Wakschlag et al. (2017) on irritability dimensions; multiple validation studies for K-SADS-PL-5, CAPA, DISCAP-5; MI/-AMDP discussions for APD; cross-cultural DMDD debates; and systematic reviews on assessment tools (Walker et al., 2020; Murkner-Lavanchy et al., 2021).

  • Core data points: prevalence estimates (ODD ~10%; CD ~9.5%; DMDD 0.1%–7%); onset ages; reliability indices (ODD interview kappa values); and multi-informant advantages/limitations.